mobileapp
80Bites Mobile App Release
August 14, 2023 09:03 ET | PhysicalMind Institute
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- PhysicalMind Institute, the company that helped bring Pilates to worldwide fame, announces the release of the 80Bites mobile application which helps an...
Obesity Canada logo-en-fr-hor-vert-F2.jpg
Study Finds Benefits of Telephone Cognitive Behavioural Therapy for Bariatric Surgery Patients
August 03, 2023 11:00 ET | Obesity Canada
TORONTO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- New research looking at the mental health and eating behaviours of patients 1-year after bariatric surgery has found that a short, 7-session telephone...
A Call for Help from
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
July 18, 2023 09:29 ET | Spherix Global Insights
Exton, Pennsylvania, July 18, 2023 (GLOBE NEWSWIRE) -- Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight,...
Cardiometabolic Heal
Cardiometabolic Health Congress (CMHC) Launches Focused Digital Education Hubs
July 13, 2023 11:00 ET | Cardiometabolic Health Congress
Boca Raton, FL, July 13, 2023 (GLOBE NEWSWIRE) -- The digital education from worldwide cardiometabolic event leader CMHC has undergone a reorganization. A vast collection of webinars, CME...
Picture3.jpg
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
July 11, 2023 08:30 ET | Clearmind Medicine Inc.
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
zealand_logo_RGB_01.png
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
July 03, 2023 06:01 ET | Zealand Pharma
Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396...
Logo.png
Obesity Market to Witness a Robust Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Amgen, Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer, Raziel, Altimmune, Saniona, YSOPIA, Innovent
June 27, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, June 27, 2023 (GLOBE NEWSWIRE) -- Obesity Market to Witness a Robust Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Amgen, Novo Nordisk, Eli Lilly and Company,...
zealand_logo_RGB_01.png
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
June 24, 2023 11:35 ET | Zealand Pharma
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean...
zealand_logo_RGB_01.png
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
June 23, 2023 17:15 ET | Zealand Pharma
Press Release­­­­­­­ No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with...
Picture3.jpg
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023 09:05 ET | Clearmind Medicine Inc.
The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary...